Menu Search
Equities

Piramal Pharma Ltd

PPLPHARMA:NSI

Piramal Pharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)281.55
  • Today's Change-11.25 / -3.84%
  • Shares traded6.42m
  • 1 Year change+138.70%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 10:29 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Piramal Pharma Ltd grew revenues 15.39% from 70.82bn to 81.71bn while net income improved from a loss of 1.86bn to a gain of 178.20m.
Gross margin63.69%
Net profit margin0.52%
Operating margin31.03%
Return on assets0.30%
Return on equity0.58%
Return on investment0.43%
More ▼

Cash flow in INRView more

In 2024, Piramal Pharma Ltd increased its cash reserves by 311.78%, or 1.66bn. The company earned 10.05bn from its operations for a Cash Flow Margin of 12.29%. In addition the company used 4.34bn on investing activities and also paid 4.22bn in financing cash flows.
Cash flow per share6.13
Price/Cash flow per share46.19
Book value per share59.91
Tangible book value per share28.26
More ▼

Balance sheet in INRView more

Piramal Pharma Ltd has a Debt to Total Capital ratio of 37.71%, a lower figure than the previous year's 38.11%.
Current ratio1.03
Quick ratio0.5603
Total debt/total equity0.6053
Total debt/total capital0.3771
More ▼

Growth rates in INR

Year on year, growth in earnings per share excluding extraordinary items increased 109.09%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		130.36
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.